As medicines—especially those that treat conditions such as anxiety or depression—are becoming more complex, it’s not just the mix of active ingredients that generic drugmakers have to replicate. It’s also the release mechanism.
While making opioid prescriptions harder to get, Indiana’s crackdown helped spur a twofold increase in robberies of pharmacies that exacerbated the state’s standing as No. 1 in the nation for those crimes.
The companies say the drug, now in late-stage clinical trials, could be more effective for pain treatment than opioids—a dangerous category of pain killers that includes hydrocodone, morphine and fentanyl—without the abuse potential of such medications.
The owner and the director of compliance for Noblesville-based Pharmakon Pharmaceuticals Inc. have been charged with multiple criminal counts related to the sale of over-potent compounded painkillers that sickened at least three infants.
America's three insulin manufacturers—Indianapolis-based Eli Lilly and Co., Sanofi and Novo Nordisk—would face fines of $5,000 daily if they fail to provide the data.
In statehouses across the country and in Congress, drugmaker Alkermes is pushing its own addiction treatment while contributing to misconceptions and stigma about other medications used to treat opioid addiction.
The court's unanimous ruling Monday means a loss of billions in sales to makers of original versions of biologic drugs.
Besides contributing to overdoses, abuse of Opana ER was blamed for a 2015 outbreak of HIV and hepatitis C in southern Indiana linked to sharing needles, according to the FDA.
A set of consolidated lawsuits accuse AbbVie and other makers of testosterone-replacement medicines, including Eli Lilly and Co., of hiding or downplaying their products’ risk for blood clots or other serious injuries.
Top pharmaceutical CEOs say they expect President Donald Trump, a frequent critic of industry pricing practices, to take steps soon to address high U.S. drug costs.
After several years in which the value of its assets swelled, philanthropic giant Lilly Endowment Inc. watched its coffers shrink 12.7 percent in 2016 from about $11.8 billion to $10.3 billion.
Leigh Ann Pusey will join Eli Lilly and Co. next month as senior vice president for corporate affairs and communications.
Lilly is in a race with several pharmaceutical firms to develop migraine treatments using an approach known as anti-CGRP and that could create a multibillion-dollar market.
The lobby group, Pharmaceutical Research and Manufacturers of America—which counts Eli Lilly and Co. as a member—is proposing that to remain a member, companies will have to spend $200 million a year on research and development.
The struggling grocery chain told employees Friday morning that it plans to discontinue pharmacy operations and has sold customer prescription files to a national drug store chain.
Express Scripts Holding Co. shares rose Wednesday after health insurer Anthem Inc., its biggest client, said it hasn’t ruled out using the pharmacy benefit manager after their contract expires.
Shares in Eli Lilly and Co. stock fell more than 3 percent Tuesday after the Indianapolis-based drugmaker released a quarterly earnings report that showed sales of potential blockbuster drug Jardiance missed expectations by a wide margin.
The prescription drug manager said Indianapolis-based Anthem Inc., its biggest customer, doesn’t plan to extend its contract when it expires even though Express Scripts is offering major discounts.
Safis Solutions LLC, a 15-year-old Indianapolis consulting firm that helps life science companies move their products through the government regulatory process, has been acquired by PharmaLex, the companies announced Monday.
News that federal regulators rejected Lilly’s drug for arthritis sent the stock tumbling more than 5 percent Monday, and sent surprised analysts searching for answers.
